Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 18/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16308132 | 0.94 | PIK3CB (0.46) | PIK3CBPIK3CDPIK3CAPIK3CGPDCD1 | |
| SCHEMBL16308131 | 0.94 | PIK3CB (0.46) | PIK3CBPIK3CDPIK3CAPIK3CGPDCD1 | |
| SCHEMBL16308099 | 0.92 | PDCD1 (0.49) | PIK3CBPIK3CDPIK3CAPIK3CGPDCD1 | |
| SCHEMBL16308130 | 0.92 | PDCD1 (0.49) | PIK3CBPIK3CDPIK3CAPIK3CGPDCD1 | |
| SCHEMBL10125263 | 0.90 | PIK3CB (0.44) | PIK3CBPIK3CDPIK3CAPIK3CGPDCD1 | |
| SCHEMBL16308116 | 0.89 | PIK3CB (0.53) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL15029595 | 0.89 | PIK3CB (0.45) | PIK3CBPIK3CDPIK3CAPIK3CGPDCD1 | |
| SCHEMBL16308133 | 0.85 | PIK3CB (0.49) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL16308158 | 0.85 | PIK3CB (0.51) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL16308156 | 0.85 | PIK3CB (0.51) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912180-B2 | Heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2014-12-16 | — | — | US | disclosed |